Pharmacological Frontiers: The Rise of Selective Na1.8 Inhibition for Pain Management.

COI Statement

Declarations. Funding: Not applicable. Conflict of interests: Ali H. Eid has no conflicts of interest to report. Ethics approval: Not applicable. Consent participation and publication: Not applicable. Data availability: Data sharing not applicable to this article as no datasets were generated or analyzed during the current study. Code availability: Not applicable.

References:

• Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, et al. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain. 2020;161(9):1976–82.
• Catterall WA. Voltage gated sodium and calcium channels: discovery, structure, function, and pharmacology. Channels (Austin). 2023;17(1):2281714.
• Fan X, Huang J, Jin X, Yan N. Cryo-EM structure of human voltage-gated sodium channel Na(v)1.6. Proc Natl Acad Sci U S A. 2023;120(5): e2220578120.
• Sanchez-Sandoval AL, Hernandez-Plata E, Gomora JC. Voltage-gated sodium channels: from roles and mechanisms in the metastatic cell behavior to clinical potential as therapeutic targets. Front Pharmacol. 2023;14:1206136.
• Rabert DK, Koch BD, Ilnicka M, Obernolte RA, Naylor SL, Herman RC, et al. A tetrodotoxin-resistant voltage-gated sodium channel from human dorsal root ganglia, hPN3/SCN10A. Pain. 1998;78(2):107–14.